1. A golf ball having a non-uniform density, wherein the golf ball is divided into 10 layers, each of said layers having volumes which are the same and which are concentric with each other, and the layer having the highest weight is one or more layers among layers including the first layer from the central point of the golf ball to the sixth layer from the central point.
2. The golf ball according to claim 1, wherein the layer having the highest weight is any one layer among the layers including the first layer from the central point of the golf ball to the sixth layer from the central point.
3. The golf ball according to claim 2, wherein the layer having the highest weight is any one layer among layers including the first layer from the central point of the golf ball to the fifth layer from the central point.
4. The golf ball according to claim 1, wherein the layer having the highest weight is one or more layers among layers including the second layer from the central point of the golf ball to the fourth layer from the central point.
5. A golf ball having a non-uniform density, wherein the golf ball is divided into 9 layers, each of said layers having volumes which are the same and which are concentric with each other, and the layer having the highest weight is one or more layers among layers including the first layer from the central point of the golf ball to the fifth layer from the central point.
6. The golf ball according to claim 5, wherein the layer having the highest weight is any one layer among the layers including the first layer from the central point of the golf ball to the fifth layer from the central point.
7. The golf ball according to claim 6, wherein the layer having the highest weight is any one layer among layers including the first layer from the central point of the golf ball to the fourth layer from the central point.
8. The golf ball according to claim 5, wherein the layer having the highest weight is one or more layers among layers including the second layer from the central point of the golf ball to the fourth layer from the central point.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. Combined use of roflumilast and R,R-formoterol in preventing the symptoms of, or treating a respiratory tract disorder in humans.
2. Combined use of roflumilast and R,R-formoterol in preventing the symptoms of, or treating a respiratory tract disorder in humans, which comprises administering roflumilast in a daily dosage of from 100 to 500 \u03bcg and R,R-formoterol in a daily dosage of from 10 to 120 \u03bcg.
3. Medicament suited for the combined use according to claim 1 or 2, which comprises roflumilast and R,R-formoterol in fixed or free combination.
4. Medicament according to claim 3, which is a fixed oral combination.
5. Medicament according to claim 3, which is a fixed oral combination containing roflumilast in a daily dosage of from 100 to 500 \u03bcg and R,R-formoterol in a daily dosage of from 10 to 120 \u03bcg.
6. Medicament according to claim 3, which is a free combination comprising roflumilast in an oral formulation and R,R-formoterol in a formulation suited for administration by inhalation.
7. Medicament according to claim 3, which is a free combination comprising roflumilast in an oral formulation in a daily dosage of from 100 to 500 \u03bcg and R,R-formoterol in a formulation suited for administration by inhalation in a daily dosage of from 10 to 50 \u03bcg.
8. Medicament according to claim 3, which is a medicament pack containing two pack units with roflumilast in an oral formulation and R,R-formoterol in a formulation suited for administration by inhalation.
9. Method for preventing or reducing the onset of symptoms of a pulmonary disease, or treating or reducing the severity of a pulmonary disease by administering to a patient in need thereof an effective amount of roflumilast and R,R-formoterol either in a single combined form, separately, or separately and sequentially where the sequential administration is close in time, or remote in time.
10. Method according to claim 9, which comprises administering roflumilast in a daily dosage of from 100 to 500 \u03bcg and R,R-formoterol in a daily dosage of from 10 to 50 \u03bcg.
11. Medicament pack, containing roflumilast as active ingredient, which contains a description that roflumilast can be administered, for reducing the onset of symptoms of a pulmonary disease, or for treating or reducing the severity of a pulmonary disease, together with R,R-formoterol sequentially, where the sequential administration is close in time, or remote in time in any order whatever.
12. Medicament pack, containing R,R-formoterol as active ingredient, which contains a description that R,R-formoterol can be administered, for reducing the onset of symptoms of a pulmonary disease, or for treating or reducing the severity of a pulmonary disease, together with roflumilast sequentially, where the sequential administration is close in time, or remote in time in any order whatever.